| Q47557571 | A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study |
| Q35643633 | A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent. |
| Q51265028 | A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. |
| Q36636422 | Achieving fasting and postprandial blood glucose control in type 2 diabetes |
| Q40553689 | Acute and long-term effects of nateglinide on insulin secretory pathways |
| Q34025740 | Adipsin is an adipokine that improves β cell function in diabetes |
| Q42017476 | Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q37677036 | Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus |
| Q37101311 | Beta cell mass in diabetes: a realistic therapeutic target? |
| Q92697166 | Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea |
| Q44442863 | Childhood obesity and type 2 diabetes: the frightening epidemic |
| Q28473974 | Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells |
| Q39004656 | Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus. |
| Q33686766 | Clinical and genetic determinants of progression of type 2 diabetes: a DIRECT study |
| Q35822130 | Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study |
| Q38057019 | Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus |
| Q37416127 | Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. |
| Q33903076 | Comparative tolerability of sulphonylureas in diabetes mellitus |
| Q37348197 | Correlation of severity of coronary artery disease with insulin resistance. |
| Q35734015 | Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective |
| Q36480971 | Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. |
| Q39324408 | DIABETIC KETOACIDOSIS: A COMMON DEBUT OF DIABETES AMONG AFRICAN AMERICANS WITH TYPE 2 DIABETES. |
| Q40718093 | DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks |
| Q34710819 | Dapagliflozin for the treatment of type 2 diabetes: a review of the literature |
| Q90733533 | Defining Disease Progression and Drug Durability in Type 2 Diabetes Mellitus |
| Q33610728 | Defining and characterizing the progression of type 2 diabetes |
| Q35968784 | Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study |
| Q34142893 | Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis |
| Q34997002 | Diabetes management in the primary care setting: summary |
| Q37156679 | Diabetes mellitus: an opportunity for therapy with stem cells? |
| Q37299682 | Diabetes screening, diagnosis, and therapy in pediatric patients with type 2 diabetes. |
| Q38600789 | Does nutritional counseling in telemedicine improve treatment outcomes for diabetes? A systematic review and meta-analysis of results from 92 studies |
| Q38245901 | Dorothy Hodgkin Lecture 2014. Understanding genes identified by genome-wide association studies for type 2 diabetes |
| Q38762377 | Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. |
| Q37104861 | Early-onset Type 2 diabetes mellitus: an increasing phenomenon of elevated cardiovascular risk |
| Q44010115 | Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada |
| Q57093273 | Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study |
| Q36868320 | Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. |
| Q43853440 | Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study |
| Q39393777 | Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis. |
| Q36366176 | Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial |
| Q35225372 | Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial |
| Q35214435 | Enhanced glycemic control with combination therapy for type 2 diabetes in primary care |
| Q44216416 | Evaluation of alternative strategies for optimizing glycemia: progress to date |
| Q51746673 | Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment. |
| Q34727773 | Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function |
| Q33884913 | Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years |
| Q28293505 | Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study |
| Q36235047 | Factors associated with no apparent coronary artery disease in patients with type 2 diabetes mellitus for more than 10 years of duration: a case control study. |
| Q38160275 | Fasiglifam as a new potential treatment option for patients with type 2 diabetes |
| Q37835612 | Focus on incretin-based therapies: targeting the core defects of type 2 diabetes |
| Q37236300 | Functional assessment of pancreatic beta-cell area in humans |
| Q28259606 | GPR119 agonists for the treatment of type 2 diabetes |
| Q38711541 | Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation |
| Q33585850 | Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial |
| Q35893382 | Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics |
| Q51005665 | Hypoglycemic events analysis via recurrent time-to-event (HEART) models. |
| Q51308310 | Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. |
| Q45974436 | Impending type 2 diabetes. |
| Q35667116 | Importance of Beta Cell Function for the Treatment of Type 2 Diabetes |
| Q57920434 | Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation i |
| Q34446705 | In vivo pancreatic β-cell-specific expression of antiaging gene Klotho: a novel approach for preserving β-cells in type 2 diabetes |
| Q37352290 | Increased prevalence of abnormal glucose tolerance among obese siblings of children with type 2 diabetes |
| Q51378688 | Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. |
| Q36910693 | Initiation and execution of lipotoxic ER stress in pancreatic beta-cells |
| Q37227907 | Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs |
| Q36978835 | Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes |
| Q38026582 | Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. |
| Q53475411 | Intensive insulin therapy in newly diagnosed type 2 diabetes. |
| Q24234365 | Interventions for latent autoimmune diabetes (LADA) in adults |
| Q24244270 | Interventions for latent autoimmune diabetes (LADA) in adults |
| Q37634376 | K(ATP) channelopathies in the pancreas |
| Q33628244 | Kir6.2 E23K polymorphism is related to secondary failure of sulfonylureas in non-obese patients with type 2 diabetes |
| Q51297606 | Levels of the first-phase insulin secretion deficiency as a predictor for type 2 diabetes onset by using clinical-metabolic models. |
| Q46486537 | Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes |
| Q34128192 | Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment |
| Q53880980 | Metabolic syndrome: maladaptation to a modern world. |
| Q51373277 | Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. |
| Q36847318 | Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes |
| Q35550591 | Mitochondrial dysfunction and β-cell failure in type 2 diabetes mellitus |
| Q44507814 | Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea |
| Q60167697 | No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes |
| Q44591688 | Non-obese adult onset diabetes with oral hypoglycemic agent failure: islet cell autoantibodies or reversible beta cell refractoriness? |
| Q35557360 | Pancreatic beta-cell loss and preservation in type 2 diabetes |
| Q41054906 | Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy |
| Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q34181995 | Pharmacogenetics of Anti-Diabetes Drugs |
| Q35821479 | Pharmacological treatment of type 2 diabetes |
| Q45288350 | Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens |
| Q96135149 | Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus |
| Q39301518 | Possible hypoglycemic effect of Aloe vera L. high molecular weight fractions on type 2 diabetic patients |
| Q26747696 | Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes |
| Q35989381 | Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus |
| Q36828932 | Progressive deterioration of β-cell function in obese youth with type 2 diabetes |
| Q51739972 | RNA-Seq Analysis of Islets to Characterise the Dedifferentiation in Type 2 Diabetes Model Mice db/db. |
| Q42718198 | Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises |
| Q91719504 | Rapid progression of type 2 diabetes and related complications in children and young people-A literature review |
| Q47279292 | Rates of glycaemic deterioration in a real-world population with type 2 diabetes. |
| Q37351709 | Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control |
| Q51570892 | Reversibility of hyperglycaemia and islet abnormalities in the high fat-fed female ZDF rat model of type 2 diabetes. |
| Q64085679 | Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial |
| Q36131766 | Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus |
| Q35987411 | Rosiglitazone RECORD study: glucose control outcomes at 18 months |
| Q34460468 | SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes |
| Q46520634 | Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus |
| Q39862439 | Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats. |
| Q24186660 | Sulphonylurea monotherapy for patients with type 2 diabetes mellitus |
| Q24197884 | Sulphonylurea monotherapy for patients with type 2 diabetes mellitus |
| Q35839894 | Surface plasmon resonance reveals a different pattern of proinsulin autoantibodies concentration and affinity in diabetic patients |
| Q51244688 | The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis. |
| Q40201107 | The TRPA1 channel and oral hypoglycemic agents: is there complicity in β-cell exhaustion? |
| Q38602464 | The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes |
| Q33577817 | The characteristics of newly diagnosed adult early-onset diabetes: a population-based cross-sectional study |
| Q51314532 | The effect of glibenclamide on insulin secretion at normal glucose concentrations. |
| Q51371795 | The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats. |
| Q82380769 | The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes |
| Q36063768 | The management of type 2 diabetes mellitus in children and adolescents |
| Q33752751 | The natural history of type 2 diabetes. Implications for clinical practice |
| Q35085591 | The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes |
| Q35807254 | The role of sulphonylureas in the management of type 2 diabetes mellitus |
| Q39153152 | The undoing and redoing of the diabetic β-cell |
| Q43194885 | Triple fixed drug combinations in type 2 diabetes |
| Q34977225 | Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus |
| Q37707407 | Type 2 diabetes in children and adolescents. |
| Q27016644 | Type 2 diabetes: etiology and reversibility |
| Q37161925 | Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents |
| Q34131203 | Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. |
| Q33380396 | Why treatment fails in type 2 diabetes |
| Q36190631 | Youth type 2 diabetes: insulin resistance, beta-cell failure, or both? |
| Q38835019 | Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities |
| Q49955808 | β-Cell Function Over Time in Adolescents With New Type 2 Diabetes and Obese Adolescents Without Diabetes |